Julia P. Dunn, MD, MS is Associate Vice President at Eli Lilly and Company in Late Phase Development, Cardiometabolic Health. Since joining Lilly in 2020, she has supported design of registration programs including SURMOUNT-OSA with tirzepatide and the ENLIGHTEN program investigating eloralintide for weight management. She also supported design of the SURMOUNT-5 and SURMOUNT-MAINTAIN trials with tirzepatide.